Background

Angelman syndrome (AS) is a rare neurodevelopmental disorder accompanied by severe cognitive developmental delay, language impairment, ataxia, and sleep dysfunction. The primary cause is identified as the deletion or loss of function of the maternal ubiquitin-protein ligase E3A (UBE3A) gene located on the long arm of chromosome 15. UBE3A is a key enzyme that attaches ubiquitin to unnecessary or damaged proteins within cells to induce proteasomal degradation.

When the maternal UBE3A gene is lost, normal protein homeostasis collapses throughout the nervous system. While the scientific community has recognized that UBE3A deficiency triggers the disease, it has failed to provide a clear answer as to which specific substrate proteins this enzyme targets for degradation. This was because it was difficult to identify the key molecule that accumulates abnormally in neurons immediately following UBE3A deficiency and causes the pathology.

Existing studies were mostly limited to analyzing whole brain tissue of AS animal models or observing changes in gene expression levels. In this process, a discrepancy arose between transcriptomic changes and actual protein expression levels, revealing the limitation of failing to precisely capture neuronal subtype-specific characteristics. Without uncovering the fundamental molecular mechanism of the disease, researchers had to rely on symptomatic treatments to alleviate symptoms.

Key Findings

Researchers conducted multi-faceted genetic and proteomic analyses by combining human-derived neuron models and AS genetically engineered mouse models. Using human neurons differentiated from patient-derived induced pluripotent stem cells (iPSCs), they reproduced the UBE3A deficiency environment and performed a full survey of protein concentration changes using ultra-high-resolution mass spectrometry.

As a result of the analysis, it was revealed that asparagine synthetase (ASNS) abnormally accumulates in UBE3A-deficient neurons. It has been established that UBE3A acts as a degradation regulator that maintains appropriate intracellular concentrations by ubiquitinating ASNS. When UBE3A enzyme function ceased, the levels of undegraded ASNS protein surged within neurons.

This ASNS overexpression phenomenon was observed identically in the hippocampal and cortical neurons of AS mouse models. The researchers tracked how protein accumulation changes the electrophysiological characteristics of neurons. The excessive accumulation of ASNS disrupted the balance between excitatory and inhibitory synaptic transmission in neurons, distorted synaptic efficacy, and induced hyperexcitability seizures. Motor control abnormalities and impaired learning and memory observed at the mouse individual level were also directly linked to the excessive accumulation of ASNS. Lowering ASNS levels to normal through genetic manipulation or pharmacological intervention significantly restored damaged synaptic plasticity and behavioral abnormalities in mice.

Significance and Outlook

This discovery is significant because it identified the direct downstream pathological substrate of UBE3A with concrete data, a mechanism that had remained shrouded in mystery for decades. It empirically demonstrated that the trigger for AS pathogenesis is not merely a simple neurodevelopmental defect, but originates from the excessive accumulation of an enzyme protein that governs metabolism and amino acid synthesis. This marks a turning point in expanding the focus of disease research from the gene deletion itself to the abnormal mechanisms of downstream metabolic proteins.

A turning point has also been reached in terms of therapeutic strategy. In addition to the previously attempted antisense oligonucleotide (ASO)-based paternal UBE3A gene activation strategies, a clear pathway for developing small-molecule compound targeted therapies that directly inhibit the overexpressed ASNS has opened. The possibility of incorporating targeted protein degradation (TPD) technology to control enzyme activity or promote degradation is also suggested.

Challenges remain for clinical application. Since ASNS is involved in essential amino acid metabolism even in normal cells, a dosing strategy must be established to selectively control the excess accumulation within the nervous system without harming the metabolic homeostasis of other organs. Further research must also follow to determine at which stage of human brain development ASNS inhibition intervention should begin to reverse irreversible neurological damage.